BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Lv XY, Ding HG, Zheng JF, Fan CL, Li L. Rifaximin improves survival in cirrhotic patients with refractory ascites: A real-world study. World J Gastroenterol 2020; 26(2): 199-218 [PMID: 31988585 DOI: 10.3748/wjg.v26.i2.199]
URL: https://www.wjgnet.com/2307-8960/full/v26/i2/199.htm
Number Citing Articles
1
Bradley Reuter, Jasmohan S. Bajaj. MicrobiomeClinics in Liver Disease 2020; 24(3): 493 doi: 10.1016/j.cld.2020.04.006
2
T. E. Polunina. Risk stratification in alcoholic cirrhosis of the liver: a case studyMeditsinskiy sovet = Medical Council 2023; (8): 126 doi: 10.21518/ms2023-129
3
Richard J Aspinall, Mark Hudson, Stephen D Ryder, Paul Richardson, Elizabeth Farrington, Mark Wright, Robert T Przemioslo, Francisco Perez, Melanie Kent, Roland Henrar, Joe Hickey, Debbie L Shawcross. Real-world evidence of long-term survival and healthcare resource use in patients with hepatic encephalopathy receiving rifaximin-α treatment: a retrospective observational extension study with long-term follow-up (IMPRESS II)Frontline Gastroenterology 2023; 14(3): 228 doi: 10.1136/flgastro-2022-102221
4
Charles E. Gallaher, Debbie L. Shawcross. Management of Multidrug-Resistant Infections in CirrhosisSeminars in Liver Disease 2022; 42(02): 173 doi: 10.1055/a-1765-0056
5
Xiaoli Hua, Hao Feng. Changes in intestinal microbiota of HBV-associated liver cirrhosis with/without hepatic encephalopathyMedicine 2022; 101(33): e29935 doi: 10.1097/MD.0000000000029935
6
Roman Maslennikov, Aliya Alieva, Elena Poluektova, Yury Zharikov, Andrey Suslov, Yana Letyagina, Ekaterina Vasileva, Anna Levshina, Evgenii Kozlov, Vladimir Ivashkin. Sarcopenia in cirrhosis: Prospects for therapy targeted to gut microbiotaWorld Journal of Gastroenterology 2023; 29(27): 4236-4251 doi: 10.3748/wjg.v29.i27.4236
7
Paolo Caraceni, Victor Vargas, Elsa Solà, Carlo Alessandria, Koos de Wit, Jonel Trebicka, Paolo Angeli, Rajeshwar P. Mookerjee, François Durand, Elisa Pose, Aleksander Krag, Jasmohan S. Bajaj, Ulrich Beuers, Pere Ginès. The Use of Rifaximin in Patients With CirrhosisHepatology 2021; 74(3): 1660 doi: 10.1002/hep.31708
8
Aleksander Krag, Jasmohan S. Bajaj. Portal Hypertension VII2022; : 311 doi: 10.1007/978-3-031-08552-9_26
9
Jasmohan S Bajaj, Amirhossein Shamsaddini, Chathur Acharya, Andrew Fagan, Masoumeh Sikaroodi, Edith Gavis, Sara McGeorge, Alexander Khoruts, Michael Fuchs, Richard K Sterling, Hannah Lee, Patrick M Gillevet. Multiple bacterial virulence factors focused on adherence and biofilm formation associate with outcomes in cirrhosisGut Microbes 2021; 13(1) doi: 10.1080/19490976.2021.1993584
10
Aldo Torre, Jacqueline Córdova-Gallardo, Alberto C Frati Munari. Rifaximin Alfa and Liver Diseases: More Than a Treatment for Encephalopathy, a Disease ModifierTherapeutics and Clinical Risk Management 2023; : 839 doi: 10.2147/TCRM.S425292
11
Ne’matjon Mamasoliev, Ibragim Askarov, Nasrulla Khakimov, Burkhonjon Usmonov, Oybek Umurzaqov, Bakhtiyor Nazarov, M.-T. Liong, I.V. Tkacheva. Liver cirrhosis in the elderly population: analysing prevalence and gender characteristics within the biotechnological frameworkBIO Web of Conferences 2024; 84: 03004 doi: 10.1051/bioconf/20248403004
12
Rui-fang Zhu, Yu-lu Gao, Sue-Ho Robert, Jin-ping Gao, Shi-gui Yang, Chang-tai Zhu. Systematic review of the registered clinical trials for coronavirus disease 2019 (COVID-19)Journal of Translational Medicine 2020; 18(1) doi: 10.1186/s12967-020-02442-5
13
Maria J. Duarte, Phyllis C. Tien, Ma Somsouk, Jennifer C. Price. The human microbiome and gut–liver axis in people living with HIVCurrent HIV/AIDS Reports 2023; 20(3): 170 doi: 10.1007/s11904-023-00657-x
14
Igor G. Bakulin, Inna A. Oganezova, Maria I. Skalinskaya, Ekaterina V. Skazyvaeva. Liver cirrosis and complication risk managementTerapevticheskii arkhiv 2021; 93(8): 963 doi: 10.26442/00403660.2021.08.200917
15
Li Wang, Zheng-Min Cao, Li-Li Zhang, Juan-mei Li, Wen-liang Lv. The Role of Gut Microbiota in Some Liver Diseases: From an Immunological PerspectiveFrontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.923599
16
Paolo Caraceni, Juan G. Abraldes, Pere Ginès, Phil N. Newsome, Shiv K. Sarin. The search for disease-modifying agents in decompensated cirrhosis: From drug repurposing to drug discoveryJournal of Hepatology 2021; 75: S118 doi: 10.1016/j.jhep.2021.01.024
17
MohammadMahdi Saeidinejad, Ahmed Elshabrawi, Supachaya Sriphoosanaphan, Fausto Andreola, Gautam Mehta, Banwari Agarwal, Rajiv Jalan. Novel Therapeutic Approaches in Treatment of Acute-on-Chronic Liver FailureSeminars in Liver Disease 2023; 43(04): 429 doi: 10.1055/s-0043-1776773
18
Keiji Yokoyama, Hiromi Fukuda, Ryo Yamauchi, Masashi Higashi, Takashi Miyayama, Tomotaka Higashi, Yotaro Uchida, Kumiko Shibata, Naoaki Tsuchiya, Atsushi Fukunaga, Kaoru Umeda, Kazuhide Takata, Takashi Tanaka, Satoshi Shakado, Shotaro Sakisaka, Fumihito Hirai. Long-Term Effects of Rifaximin on Patients with Hepatic Encephalopathy: Its Possible Effects on the Improvement in the Blood Ammonia Concentration Levels, Hepatic Spare Ability and Refractory AscitesMedicina 2022; 58(9): 1276 doi: 10.3390/medicina58091276
19
Kensuke Kitsugi, Kazuhito Kawata, Hidenao Noritake, Takeshi Chida, Kazuyoshi Ohta, Jun Ito, Shingo Takatori, Maho Yamashita, Tomohiko Hanaoka, Masahiro Umemura, Moe Matsumoto, Takafumi Suda. Rifaximin Improves Liver Functional Reserve by Regulating Systemic InflammationJournal of Clinical Medicine 2023; 12(6): 2210 doi: 10.3390/jcm12062210
20
Thomas H. Tranah, Victoria T. Kronsten, Debbie L. Shawcross. Implications and Management of Cirrhosis‐Associated Immune Dysfunction Before and After Liver TransplantationLiver Transplantation 2022; 28(4): 700 doi: 10.1002/lt.26353
21
Xiao Yu, Ye Jin, Wangxiao Zhou, Tingting Xiao, Zhongwen Wu, Junwei Su, Hainv Gao, Ping Shen, Beiwen Zheng, Qixia Luo, Lanjuan Li, Yonghong Xiao. Rifaximin Modulates the Gut Microbiota to Prevent Hepatic Encephalopathy in Liver Cirrhosis Without Impacting the ResistomeFrontiers in Cellular and Infection Microbiology 2022; 11 doi: 10.3389/fcimb.2021.761192
22
皓月 田. The Application of Rifaximin in Patients with End Stage Liver DiseaseAdvances in Clinical Medicine 2024; 14(01): 466 doi: 10.12677/ACM.2024.141067
23
Mei‐Tong Nie, Pei‐Qin Wang, Pei‐Mei Shi, Xia‐Lu Hong, Xin Zhang, Baoyu Xiang, Menghui Zhang, Wei‐Fen Xie. Rifaximin treatment shapes a unique metagenome‐metabolism network in patients with decompensated cirrhosisJournal of Gastroenterology and Hepatology 2024;  doi: 10.1111/jgh.16484
24
Giacomo Zaccherini, Manuel Tufoni, Mauro Bernardi, Paolo Caraceni. Prevention of Cirrhosis Complications: Looking for Potential Disease Modifying AgentsJournal of Clinical Medicine 2021; 10(19): 4590 doi: 10.3390/jcm10194590
25
Simona Parisse, Quirino Lai, Francesca Martini, Alice Martini, Flaminia Ferri, Monica Mischitelli, Fabio Melandro, Gianluca Mennini, Massimo Rossi, Domenico Alvaro, Stefano Ginanni Corradini. Rifaximin Reduces Risk of All-Cause Hospitalization in Cirrhotic Liver Transplant Candidates with Hepatic EncephalopathyJournal of Clinical Medicine 2023; 12(21): 6871 doi: 10.3390/jcm12216871